skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

14 Total results for product and free and sample content found

Clinical trial intelligence

Pharmaprojects

AiCuris seeks partners for antibacterial programs

07 Dec 2016

AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. Zimmermann highlights AiCuris's anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans. AiCuris already has an exclusive worldwide licensing agreement in place with Merck & Co. for its lead compound, letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of human cytomegalovirus (HCMV) infection in transplant recipients. AiCuris received a EUR 110 million upfront payment from Merck as part of this deal, which covers AiCuris's novel portfolio of investigational HCMV medicines.

Clinical trial intelligence

Pharmaprojects

BioNTechs Sean Marett explains Genentech deal rationale

07 Dec 2016

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.

Clinical trial intelligence

Pharmaprojects

Cinfa outlines biosimilar development areas and deal opportunities

07 Dec 2016

Cinfa Biotech's managing director, Ruediger Jankowsky, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company's founding and focus on biosimilar drug development. They discuss Cinfa's biosimilars business model, disease areas of focus and potential deals for the company in the near future.

Clinical trial intelligence

Pharmaprojects

Dimerix CEO explains companys different drug combo R and D strategy

07 Dec 2016

Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company's unusual business model. They discuss Dimerix's Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix's pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix's lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.

Clinical trial intelligence

Pharmaprojects

eTheRNA CEO outlines development plan in cancer RNA space

07 Dec 2016

Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe® partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

Clinical trial intelligence

Pharmaprojects

F star business chief discuss Denali deal and potential F star delta spinout

07 Dec 2016

Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star's asset-centric business strategy, the company's recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.

Clinical trial intelligence

Pharmaprojects

How are regulatory changes affecting early stage R and D in China

07 Dec 2016

Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China.  Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.

RxScorecard

Examine How Payers Make Reimbursement Decisions

By Roger Longman 21 Nov 2016

Topics Reimbursement

Business and portfolio strategy Competitive and market intelligence

Datamonitor Healthcare

Inside the payer perspective market

08 Nov 2016

Topics Reimbursement

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: